FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA Peptide Category 2 Removal & Public Meeting July 23rd Mansi Hukmani posted on the topic LinkedIn FDA Peptide Reclassification 2026: What It Means for Providers The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what